Chemotherapy negatively impacts body composition, physical function and metabolic profile in patients with breast cancer

Godinho-Mota, Jordana Carolina Marques; Mota, João Felipe; Vaz-Gonçalves, Larissa; Soares, Leonardo Ribeiro; Schincaglia, Raquel Machado; Prado, Carla M.; Martins, Karine A.; Freitas‐Júnior, Ruffo

doi:10.1016/j.clnu.2020.11.020

Cited by 23 publications

(21 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason may be alternations in the distribution, metabolism and clearance of chemotherapeutic drugs(26). In this study, lean tissues were decreased and fat tissues were increased after induction chemotherapy, which was also observed in breast cancer patients (27). Muscle and adipose tissue are the major sites of distribution of hydrophilic and lipophobic drugs, respectively.…”

Section: Discussionsupporting

confidence: 65%

Changes in body composition of patients with acute leukemia during induction and consolidation chemotherapies

Zou

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: Malnutrition is detrimental to the treatment and prognosis of patients with acute leukemia (AL). Body composition analysis is a reliable method to monitor and assess the nutritional status of patients. However, there are few studies focusing on body composition changes of patients with AL undergoing chemotherapy.Methods: Patients who were newly-diagnosed with AL were enrolled in this study. The body composition was measured before and after induction and consolidation chemotherapies. Paired-samples T test and multiple linear regression analysis were used to compare body composition changes and explore the influencing factors.Results: After induction chemotherapy, weight, body mass index (BMI), total body water, fat free mass (FFM), skeletal muscle mass (SMM) and basal metabolic rate were significantly decreased, but fat mass (FM), percentage of body fat (PBF) and visceral fat area (VFA) were significantly increased. There were no significant changes in body composition during consolidation chemotherapy. Multivariate analysis showed that age was negatively related to declines in weight, BMI, FFM and SMM during induction chemotherapy and acute myelocytic leukemia patients dropped less in FFM and SMM and increased less in PBF and VFA, compared with acute lymphocytic leukemia (ALL).Conclusion: Decreased FFM and increased FM were seen in AL patients after induction chemotherapy. Conventional nutritional monitoring and timely support are very important for patients with AL during chemotherapy, especially for ALL patients.

show abstract

Section: Discussionsupporting

confidence: 65%

Changes in body composition of patients with acute leukemia during induction and consolidation chemotherapies

Zou

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…However, CA153 was also significantly increased in diseases such as renal impairment in type 2 diabetes [ 31 ], interstitial lung disease [ 32 ], idiopathic inflammatory myositis [ 33 ], sarcoidosis [ 34 ], and SARS-CoV-2 infection [ 35 ]. Adjuvant chemotherapy can aggravate blood glucose and blood lipid metabolic disorders while killing potential tumors [ 36 , 37 ], leaving the body in a state of chronic inflammation. Our analysis showed that “spiking” phenomenon was not only correlated with lymph node metastasis and tumor hormone receptor status but also correlated with the change of rGT and the ratio of NEUT/LY.…”

Section: Discussionmentioning

confidence: 99%

Changes of Tumor Markers in Patients with Breast Cancer during Postoperative Adjuvant Chemotherapy

et al. 2022

View full text Add to dashboard Cite

Objective. Serum tumor marker (STM) elevation can detect metastasis earlier than imaging diagnosis and, although not recommended by guidelines, is still widely used in clinical practice for postoperative follow-up of breast cancer patients. The purpose of this study was to investigate the change rules of CEA and CA153 in patients with HER2-negative breast cancer during postoperative adjuvant chemotherapy and their influencing factors. Materials and Methods. The medical records of patients with HER2-negative early breast cancer who visited Xuanwu Hospital from September 2018 to June 2021 were retrospectively analyzed. Demographic characteristics and baseline data of CEA and CA153 at initial diagnosis were collected. Data of CEA, CA153, biochemistry (including ALT, AST, rGT, triglycerides, cholesterol, and blood glucose) and blood routine (including white blood cells, neutrophils, monocytes, lymphocytes, and platelets) were also collected before chemotherapy, at the end of chemotherapy and more than 3 months after the end of chemotherapy. LY/MONO, NEUT/LY, PLT/LY, and systemic immune inflammation index (SII) were calculated and statistically analyzed using SPSSAU software. Results. A total of 90 patients were enrolled, all of whom were female, with a mean age of 55.11 ± 10.60 y. The value of CEA at initial diagnosis was 2.10 ± 1.11 ng/mL, and high expression was mostly correlated with past history of chronic diseases and tumor lymph node metastasis; the value of CA153 was 11.80 ± 6.60 U/mL, and high expression was correlated with high SII at initial diagnosis. Surgery did not affect the values of serum CEA and CA153. At the end of chemotherapy, CEA and CA153 were 2.68 ± 1.34 ng/mL and 18.51 ± 8.50 U/mL, respectively, which were significantly increased compared with those before chemotherapy, and were linearly correlated with the values before chemotherapy. They decreased (CEA 2.45 ± 1.19 ng/mL, CA153 10.87 ± 5.96 U/mL) again three months after the end of chemotherapy, manifested as “spiking” phenomenon, which was associated with lymph node metastasis at diagnosis, body metabolic disorders, and chronic inflammatory status. Conclusion. CEA and CA153 were increased presenting as “spiking” phenomena in patients with early HER2-negative breast cancer during postoperative adjuvant chemotherapy, and the peak of increase was linearly correlated with the indicators before chemotherapy. Clinical attention should be paid to this change to avoid excessive diagnosis and treatment leading to medical resource consumption.

show abstract

“…Similarly, metabolic changes are another possible consequence for those patients, such as lipids and glucose levels increase 13,14 . Moreover, Godinho-Mota et al (2020) reported a visceral fat dysfunction among breast cancer patients after chemotherapy 15 . Considering visceral fat accumulation, the adiposity indices as the visceral adiposity index (VAI), lipid accumulation product index (LAP), and triglyceride glucose index (TyG), could be important metabolic alterations tracking tools [16][17][18][19][20] .…”

Section: Introductionmentioning

confidence: 99%

An evaluation of metabolic, dietetic, and nutritional status reveals impaired nutritional outcomes in breast cancer patients undergoing chemotherapy compared with a matched control group

Silva

Rufato

Mialich

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose Nutritional status changes in breast cancer patients during treatment are prevalent, and those alterations can increase non-cancer-related comorbidities. In addition, the metabolic implications of those alterations are poorly understood. We aimed to characterize body composition, lipids, glucose levels, and indices that express cardiovascular risk in breast cancer patients after completion of chemotherapy and then to compare those results with a matched control group. Methods A cross-sectional study was performed. Women who completed their chemotherapy were recruited (BC group) and compared with a group of non-malignant age- and body mass index-matched (MC group), as well as a group of healthy, non-malignant women (HC group). Body composition by bioelectrical impedance analysis, handgrip strength, and blood sample were collected. Visceral adiposity, triglyceride glucose and lipid accumulation product indices were calculated. Food consumption was assessed. Results 88 women were included (BC=36, MC=36, HC=16). BC patients demonstrated worse values of phase angle, nutritional risk index, extracellular body water to total body water ratio and lower handgrip strength. Additionally, those women had impairments in lipids, worst glucose levels, visceral fat dysfunction and consequently higher cardiovascular risk, presenting important unhealthy dietary patterns with higher carbohydrate and caloric intake and insufficient protein and fiber ingestion. No differences were observed between MC and HC. Conclusion Breast cancer patients present unhealthy metabolic, nutritional, and dietetic features when compared to a group of age- and BMI-matched non-malignant females. Also, breast cancer patients had higher levels of cardiovascular risk. Further investigations are required to examine the underlying mechanisms and the potential longitudinal changes during surveillance time.

show abstract

Chemotherapy negatively impacts body composition, physical function and metabolic profile in patients with breast cancer

Cited by 23 publications

References 61 publications

Changes in body composition of patients with acute leukemia during induction and consolidation chemotherapies

Changes in body composition of patients with acute leukemia during induction and consolidation chemotherapies

Changes of Tumor Markers in Patients with Breast Cancer during Postoperative Adjuvant Chemotherapy

An evaluation of metabolic, dietetic, and nutritional status reveals impaired nutritional outcomes in breast cancer patients undergoing chemotherapy compared with a matched control group

Contact Info

Product

Resources

About